safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-71Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESТранспортеры органических анионов и их влияние на токсичность β-лактамных антибиотиковOrganic anion transporters and their influence on the toxicity of β-lactam antibioticsЕвтеевВ. А.EvteevV. A.noemail@neicon.ruМуслимоваО. В.MuslimovaO. V.noemail@neicon.ruМазеркинаИ. А.MazerkinaI. A.noemail@neicon.ruБунятянН. Д.BunyatyanN. D.noemail@neicon.ruШихЕ. В.ShikhE. V.noemail@neicon.ruКазаковР. Е.KazakovR. E.noemail@neicon.ruНаучный центр экспертизы средств медицинского примененияРоссияScientific Centre for Expert Evaluation of Medicinal ProductsRussian Federation201720022018527075Copyright © Евтеев В.А., Муслимова О.В., Мазеркина И.А., Бунятян Н.Д., Ших Е.В., Казаков Р.Е., 20182018Евтеев В.А., Муслимова О.В., Мазеркина И.А., Бунятян Н.Д., Ших Е.В., Казаков Р.Е.Evteev V.A., Muslimova O.V., Mazerkina I.A., Bunyatyan N.D., Shikh E.V., Kazakov R.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/71

Представлены классификация, строение и механизм действия транспортеров органических анионов. Рассмотрено влияние отдельных представителей этого семейства транспортеров на фармакокинетику β-лактамных антибиотиков.

This review article describes the classification and mechanism of action of organic anion transporters (OAT). The influence of certain members of this family of transporters on the pharmacokinetics of β-lactam antibiotics.

транспортерыβ-лактамные антибиотикиSLCOAT1OAT3OAT4OATP1A2OATP1A2OATP1B1OATP1B3transportersβ-lactam antibioticsSLCOAT1OAT3OAT4OATP1A2OATP1A2OATP1B1OATP1B3ReferencesNigam SK, Bush KT, Martovetsky G, Ahn S-Y, Liu HC, Richard E, et al. The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective. Physiol Rev. 2015 Jan; 95 (1): 83-123.Nigam SK, Bush KT, Martovetsky G, Ahn S-Y, Liu HC, Richard E, et al. The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective. Physiol Rev. 2015 Jan; 95 (1): 83–123.Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res. 2007; 24: 450-470.Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res. 2007; 24: 450–470.Emami Riedmaier A, Nies AT, Schaeffeler E, Schwab M. Organic anion transporters and their implications in pharmacotherapy. Pharmacol Rev. 2012 Jul; 64(3): 421-49.Emami Riedmaier A, Nies AT, Schaeffeler E, Schwab M. Organic anion transporters and their implications in pharmacotherapy. Pharmacol Rev. 2012 Jul; 64(3): 421–49.Rammelkamp CH, Keefer CS. The absorption, excretion, and distribution of penicillin. J Clin Invest. 1943 May; 22(3): 425-37.Rammelkamp CH, Keefer CS. The absorption, excretion, and distribution of penicillin. J Clin Invest. 1943 May; 22(3): 425–37.Hagos Y, Natascha A. Wolff. Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced Nephrotoxicity. Toxins 2010, 2, 2055-2082; doi:10.3390/toxins2082055Hagos Y, Natascha A. Wolff. Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced Nephrotoxicity. Toxins 2010, 2, 2055–2082; doi:10.3390/toxins2082055Brown GR. Cephalosporin-probenecid drug interactions. Clin. Pharmacokinet. 1993; 24: 289-300.Brown GR. Cephalosporin-probenecid drug interactions. Clin. Pharmacokinet. 1993; 24: 289–300.Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 2002; 302: 666-671.Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 2002; 302: 666–671.Jaehde U, Sorgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin. Pharmacol. Ther. 1995; 58: 532-541.Jaehde U, Sorgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin. Pharmacol. Ther. 1995; 58: 532–541.Takeda ML, Babu E, Narikawa S, Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8; 438(3): 137-42.Takeda ML, Babu E, Narikawa S, Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8; 438(3): 137–42.Tune BM, Fravert D, Hsu CY. Thienamycin nephrotoxicity. Mitochondrial injury and oxidative effects of imipenem in the rabbit kidney. Biochem. Pharmacol. 1989; 38: 3779-3783.Tune BM, Fravert D, Hsu CY. Thienamycin nephrotoxicity. Mitochondrial injury and oxidative effects of imipenem in the rabbit kidney. Biochem. Pharmacol. 1989; 38: 3779–3783.Lim SC, Im YB, Bae CS, Han SI, Kim SE, Han HK. Protective effect of morin on the imipenem-induced nephrotoxicity in rabbits. Arch. Pharm. Res. 2008; 31: 1060-1065.Lim SC, Im YB, Bae CS, Han SI, Kim SE, Han HK. Protective effect of morin on the imipenem-induced nephrotoxicity in rabbits. Arch. Pharm. Res. 2008; 31: 1060–1065.Enomoto AL, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun; 301(3): 797-802.Enomoto AL, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun; 301(3): 797–802.Lee SC, Zhang L, Huang SM. Regulatory science perspectives on transporter studies in drug development. In: You G, Morris ME, eds. Drug Transporters: Molecular Characterization and Role in Drug Disposition. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2014. P. 473-487.Lee SC, Zhang L, Huang SM. Regulatory science perspectives on transporter studies in drug development. In: You G, Morris ME, eds. Drug Transporters: Molecular Characterization and Role in Drug Disposition. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2014. P. 473–487.Романов БК, Глаголев СВ, Поливанов ВА, Леонова МВ. Мониторинг безопасности лекарственных средств. Безопасность и риск фармакотерапии 2014; 3: 11-14.Romanov BK, Glagolev SV, Polivanov VA, Leonova MV. Monitoring the safety of medicines. Safety and Risk of Pharmacotherapy 2014; 3: 11–14 (in Russian).Романов БК. Кальциевая регуляция активности лизосомальных ферментов миокарда. Биомедицинская химия 2005; 6 (51): 634-642.Romanov BK. Regulation of Myocardial lysosomal enzyme activity by calcium. Biomedical Chem 2005; 6(51): 634–642 (in Russian).Снегирева ИИ, Затолочина КЭ, Озерецковский НА, Романов БК, Миронов АН. Фармаконадзор вакцин в России: нормативно-правовое регулирование, особенности развития на современном этапе. Ведомости Научного центра экспертизы средств медицинского применения 2014; 4: 27-31.Snegireva II, Zatolochina KE, Ozeretskovsky NA, Romanov BK, Mironov AN. Vaccine pharmacovigilance in Russia, legal and regulatory framework, current stage of development. Scientific Centre for Expert Evaluation of Medicinal Products Bulletin 2014; 4: 27–31 (in Russian).Романов БК, Торопова ИИ. Неправильное применение лекарственных средств. Безопасность и риск фармакотерапии 2014; 2: 28-30.Romanov BK, Toropova IA. Medication errors. Safety and Risk of Pharmacotherapy 2014; 2: 28–30 (in Russian).Kreuter J, Alyautdin RN. Using nanoparticles to target drugs to the central nervous system. The blood-brain barrier and drug delivery to the CNS. New York; 2000.Kreuter J, Alyautdin RN. Using nanoparticles to target drugs to the central nervous system. The blood- brain barrier and drug delivery to the CNS. New York; 2000.Меркулов ВА, Бунятян НД, Сакаева ИВ, Рычихина ЕМ, Лепахин ВК, Романов БК, Комратов АВ, Кошечкин КА, Козлович АВ. Совершенствование системы оценки информации о безопасности лекарственных средств при проведении клинических исследований. Ведомости Научного центра экспертизы средств медицинского применения 2014; 1: 20-26.Merkulov VA, Bunyatyan ND, Sakaeva IV, Richikhina EM, Lepakhin VC, Romanov BK, Komratov AV, Koshechkin KA, Kozlovich AV. Improving the system of evaluating information on the safety of medicines in clinical trials. The Bulletin of the Scientific center for expert evaluation of medical products 2014; 1: 20–26 (in Russian).Снегирева ИИ, Затолочина КЭ, Дармостукова МА, Аляутдин РН, Романов БК. Современные подходы к взаимозаменяемости вакцин. Ведомости Научного центра экспертизы средств медицинского применения 2016; 4: 3-8.Snegireva II, Zatolochina KE, Darmostukova MA, Alyautdin RN, Romanov BK. Modern approaches to vaccine interchangeability. The Bulletin of the Scientific center for expert evaluation of medical products 2016; 4: 3–8. (in Russian).

The authors declare that there are no conflicts of interest present.